GlassScriptPhysician profile
Stephanie Ann Schmid
NPI 1750876587
$3,347.61
in general payments reported to CMS, 2019-2025
29 companies · $726 in 2025
The $726 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $706 · 2022: $652 · 2023: $597 · 2024: $668 · 2025: $726.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,990.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,990.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $771.35 | 2021-2025 | Repatha, Repatha, Evenity |
| Abbvie INC. | $473.52 | 2021-2025 | |
| Abbott Laboratories | $472.55 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astrazeneca Pharmaceuticals LP | $352.38 | 2022-2025 | Airsupra, Breztri |
| Glaxosmithkline, LLC. | $169.73 | 2023-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Janssen Pharmaceuticals, INC | $140.00 | 2021-2024 | Xarelto |
| Pfizer INC. | $125.46 | 2021-2025 | |
| Lilly USA, LLC | $91.00 | 2022-2025 | Mounjaro |
| Boston Scientific Corporation | $77.00 | 2022 | |
| Exact Sciences Corporation | $75.67 | 2024-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $70.16 | 2021-2025 | Rybelsus, Ozempic |
| Nevro Corp. | $60.69 | 2023-2024 | Senza |
| Novartis Pharmaceuticals Corporation | $59.00 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $49.36 | 2022-2024 | Gardasil, Gardasil 9, Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $36.88 | 2023-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $35.47 | 2021-2025 | |
| Amneal Pharmaceuticals LLC | $34.17 | 2024-2025 | Unithroid |
| Nestle Healthcare Nutrition INC. | $32.46 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.73 | 2021-2023 | Xifaxan, Trulance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $27.23 | 2025 | Caplyta |
| Sumitomo Pharma America, INC. | $21.62 | 2023 | Gemtesa |
| Ascensia Diabetes Care US INC. | $20.55 | 2025 | |
| Astellas Pharma US INC | $20.31 | 2025 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $20.16 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $18.00 | 2021 | |
| Amarin Pharma, INC. | $17.73 | 2021 | |
| Sanofi-Aventis U.S. LLC | $17.61 | 2022 | |
| Sanofi Pasteur INC. | $15.67 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.15 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Schmid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.